Why Targeting Ghrelin for Appetite Control Has Been So Difficult Despite Decades of Research

Ghrelin's central brain signaling is critical for its effects on appetite, body weight, and food reward. However, multiple factors have prevented successful drug development: GHSR-1a receptor internalization and heterodimerization create complex pharmacology, biased ligand interactions produce unpredictable effects, compensatory neuroendocrine outputs counteract drug effects, and the receptor's ubiquitous expression makes it impossible to target appetite without affecting peripheral ghrelin functions. Improving blood-brain barrier penetration of ghrelin ligands, particularly to reach mesolimbic reward circuitry, is identified as a key priority.

Narrative review of the ghrelin system biology, receptor pharmacology, and therapeutic development efforts for appetite modulation, covering both preclinical and clinical evidence.

Understanding why ghrelin-targeting drugs haven't succeeded explains a major gap in the obesity and cachexia treatment landscape. While GLP-1 drugs have conquered the satiety side of appetite, the hunger side — driven by ghrelin — remains pharmacologically intractable. Solving the ghrelin drug delivery and receptor selectivity challenges could complement existing GLP-1 therapies and address conditions where appetite stimulation is needed, such as cancer cachexia and anorexia in the elderly.

The ghrelin story illustrates a common challenge in peptide drug development: understanding a peptide's biology is far easier than successfully drugging its receptor. While GLP-1 drugs succeeded in part because the receptor pharmacology was simpler, ghrelin's receptor system is more complex — heterodimerizing, internalizing, and exhibiting constitutive activity. The lessons learned from ghrelin drug development failures inform broader peptide therapeutic research and highlight the importance of brain-penetrant peptide drug design.

As a 2017 review, it predates some recent advances in ghrelin pharmacology and drug delivery. The review covers a wide scope, which limits depth on individual drug candidates. The emphasis on challenges may understate progress in understanding ghrelin biology. Some therapeutic leads mentioned may have since advanced or been abandoned.